Heron Therapeutics (NASDAQ: HRTX) revises executive severance and CIC
Heron Therapeutics has revised the employment and retention agreements for its senior leadership, including CEO Craig Collard and other key executives. The amendments enhance severance protections, particularly during change-in-control scenarios, by increasing cash payments, accelerating equity vesting, and extending health coverage benefits. The company also updated bonus mechanics, restrictive covenants, and adopted North Carolina as the governing law.
Heron Therapeutics (HRTX) CEO exercises 62,500 RSUs into common stock
Heron Therapeutics (HRTX) CEO Craig A. Collard exercised 62,500 restricted stock units (RSUs) into an equal number of common stock shares at a $0.0000 exercise price. Following this transaction, Collard directly owns 648,255 shares of Heron Therapeutics common stock, which includes 14,045 shares acquired through an Employee Stock Purchase Plan. The RSUs vest in four equal annual installments, contingent on continued service.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Average Recommendation of "Hold" by Analysts
Heron Therapeutics (NASDAQ:HRTX) has received an average "Hold" recommendation from analysts, with one analyst rating it a sell, one a hold, and three a buy, leading to an average 12-month price target of $4.50. The company recently surpassed earnings and revenue expectations, reporting an EPS of ($0.02) against an expected ($0.03) and revenue of $40.6 million against $39.5 million. Institutional investors hold approximately 80% of the stock, with several firms modifying their positions and making substantial purchases in the fourth quarter.
Vanguard realigns holdings; Heron Therapeutics (HRTX) ownership shown as 0
The Vanguard Group filed an amendment to its Schedule 13G/A, disclosing 0 beneficially owned shares of Heron Therapeutics Inc. common stock, representing 0% of the class. This change is due to an internal realignment on January 12, 2026, where certain Vanguard subsidiaries/divisions now report separately in reliance on SEC Release No. 34-39538. The filing was signed by Ashley Grim, Head of Global Fund Administration, on March 27, 2026.
What is Northland Securities' Estimate for HRTX Q3 Earnings?
Northland Securities has revised its Q3 2026 EPS estimate for Heron Therapeutics (NASDAQ:HRTX) upward to $0.00, from a previous forecast of ($0.01), and projects Q4 2026 EPS of $0.01. The consensus full-year earnings estimate for Heron Therapeutics is ($0.13) per share, and the company recently reported Q4 EPS of ($0.02), surpassing consensus by $0.01 with revenues of $40.59 million.
If You Invested $1,000 in Heron Therapeutics Inc (HRTX)
This article analyzes the historical performance of Heron Therapeutics Inc (HRTX) stock, illustrating what a $1,000 investment would be worth over 1, 5, and 10 years, showing significant losses. It details the company's business as a commercial-stage biotechnology firm focused on acute care and oncology supportive care products like ZYNRELEF, APONVIE, CINVANTI, and SUSTOL. The piece also provides a year-by-year return comparison of HRTX against the S&P 500, showing substantial underperformance.
Baker BROS. Advisors LP Purchases New Position in Heron Therapeutics, Inc. $HRTX
Baker BROS. Advisors LP initiated a new position in Heron Therapeutics (NASDAQ:HRTX) during the third quarter, acquiring over 4.25 million shares valued at approximately $5.36 million. Heron Therapeutics recently reported better-than-expected quarterly earnings, with an EPS of -$0.02 and revenue of $40.59 million. Despite mixed analyst ratings (three Buys, two Sells, resulting in an average Hold) and a consensus price target of $4.50, institutional investors hold a significant 80% stake in the company.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Average Recommendation of "Hold" by Brokerages
Heron Therapeutics (NASDAQ:HRTX) has received an average recommendation of "Hold" from five brokerages, with two analysts rating it a "sell" and three a "buy." The average 12-month price target is $4.50. Despite remaining unprofitable with a P/E of -7.44, the company slightly exceeded Q4 2025 earnings and revenue estimates.
Earnings Call Summary | Heron Therapeutics(HRTX.US) Q4 2025 Earnings Conference
Heron Therapeutics reported strong financial results for Q4 and full year 2025, exceeding original guidance with $155 million in net revenues and a 73% gross margin. The company saw significant growth in ZYNRELEF and APONVIE revenues, improved its capital structure through successful financing, and is developing a prefilled syringe for ZYNRELEF. For 2026, Heron projects net product sales of $173 million to $183 million and adjusted EBITDA of $10 million to $20 million, driven by commercial expansion and positive reimbursement changes.
HC Wainwright Has Negative Forecast for HRTX FY2026 Earnings
HC Wainwright has revised its FY2026 EPS estimate for Heron Therapeutics (NASDAQ:HRTX) to ($0.06) from ($0.05) but maintained a "Buy" rating and a $6.00 price target. This comes despite Heron Therapeutics exceeding Q4 expectations with an EPS of ($0.02) and revenue of $40.59 million, and providing optimistic FY2026 guidance for net revenue between $173-$183 million and adjusted EBITDA of $10-$20 million. Analyst sentiment for HRTX is mixed, with three Buys and two Sells, and a consensus price target of $4.50 against its current trading price of $1.19.
Heron Therapeutics (NASDAQ:HRTX) Rating Lowered to Strong Sell at Zacks Research
Zacks Research downgraded Heron Therapeutics (NASDAQ:HRTX) to a "strong sell" from a "hold" rating, despite the company modestly beating Q4 earnings and revenue estimates and issuing positive FY2026 guidance. While institutional investors have increased their holdings, overall analyst coverage remains mixed with an average "Hold" rating and a target price of $4.50. The stock is currently trading around $1.19, with a negative P/E ratio and a market cap of approximately $218 million.
HRTX Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Heron Therapeutics Inc (HRTX), based on its fiscal year 2025 performance. It covers key financial statements including the income statement, balance sheet, and cash flow, along with critical financial ratios and health signals. The company's financial profile is rated as weak with low profitability, high leverage, but strong liquidity, and it currently operates at a loss.
Heron Therapeutics (HRTX) TTM Loss Of US$20.2 Million Tests Profitability Turnaround Narrative
Heron Therapeutics (HRTX) closed FY 2025 with a Q4 revenue of US$40.6 million and a trailing 12-month net loss of US$20.2 million, translating to a basic EPS loss of US$0.12. Despite analyst narratives predicting a turnaround to profitability, the company's inconsistent quarterly results and ongoing share dilution present challenges, leading to concern among cautious investors. The article highlights both optimistic views on operational improvements and policy support, and skeptical views focusing on persistent losses and funding needs.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2025 Earnings Call Transcript
Heron Therapeutics, Inc. reported strong financial results for Q4 and the full year 2025, exceeding EBITDA guidance. The company highlighted significant growth in its Acute Care franchise, particularly ZYNRELEF and APONVIE, and outlined strategic investments for commercial expansion in 2026. Heron also provided updates on its CINVANTI litigation and the anticipated timeline for the ZYNRELEF prefilled syringe approval.
Heron Therapeutics (HRTX) grows 2025 revenue and guides to positive EBITDA
Heron Therapeutics reported a 7.4% increase in 2025 net revenue to $154.9 million, driven by a 65.1% surge in its Acute Care franchise, primarily ZYNRELEF and APONVIE. Despite a decline in Oncology revenue, the company significantly improved its adjusted EBITDA to $14.7 million. Heron has also provided a positive outlook for 2026, projecting net revenues between $173 million and $183 million and adjusted EBITDA of $10 million to $20 million, signaling continued growth and profitability.
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results
Heron Therapeutics reported strong financial results for Q4 and full-year 2025, driven by a 65% year-over-year net revenue growth in its Acute Care franchise, primarily from ZYNRELEF and APONVIE. The company achieved $154.9 million in 2025 net revenue and issued a 2026 net revenue guidance of $173 to $183 million and adjusted EBITDA of $10 to $20 million. Key drivers include enhanced distributor incentives, completed Vial Access Needle transition, and CMS approval of product-specific J-Codes for ZYNRELEF, along with APONVIE's inclusion in PONV guidelines and a dedicated sales team.
Heron Therapeutics (HRTX) TTM Loss Of US$20.2 Million Tests Profitability Turnaround Narrative
Heron Therapeutics (HRTX) reported a Q4 revenue of US$40.6 million and a TTM net loss of US$20.2 million, with a basic EPS loss of US$0.12. Despite narratives of a profitability turnaround, the company's TTM losses and quarterly swings in net income highlight challenges in achieving consistent profitability. Cautionary investors are concerned about ongoing losses and share dilution, while bullish arguments point to revenue stability and potential operational improvements in the non-opioid therapy market.
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results
Heron Therapeutics reported strong financial results for Q4 and full-year 2025, driven by a 65% year-over-year net revenue growth in its Acute Care franchise, primarily from ZYNRELEF and APONVIE. The company achieved $154.9 million in net revenue for 2025 and issued a full-year 2026 net revenue guidance of $173 million to $183 million, alongside an Adjusted EBITDA guidance of $10 million to $20 million. Key achievements include CMS approval of product-specific J-Codes for both ZYNRELEF and APONVIE, and the completion of the ZYNRELEF Vial Access Needle transition, which are expected to further accelerate adoption and revenue expansion.
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results
Heron Therapeutics announced robust financial results for Q4 and full-year 2025, driven by significant net revenue growth of 65% year-over-year in its Acute Care franchise, primarily from ZYNRELEF and APONVIE. The company projects 2026 net revenue to be between $173 million and $183 million, with adjusted EBITDA of $10 million to $20 million, citing strong commercial momentum and strategic achievements like J-Code approvals for its key products. Despite a decline in the Oncology franchise revenue, overall total net revenue increased by 7.4% to $154.9 million for the fiscal year 2025.
Heron Therapeutics, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:HRTX)
Heron Therapeutics, Inc. has published its Q4 2025 earnings call presentation, reporting an EPS of -$0.02, beating estimates by $0.01, and revenue of $40.59M, exceeding expectations by $1.05M. The revenue figure represents a slight year-over-year decrease of 0.47%. This presentation provides details discussed during their recent earnings call.
Heron Therapeutics: Fourth Quarter Earnings Overview
Heron Therapeutics Inc. reported a net loss of $3 million, or 2 cents per share, for its fourth quarter, with revenues reaching $40.6 million. For the entire fiscal year, the company posted a total loss of $20.2 million on $154.9 million in revenue. Looking ahead, Heron Therapeutics projects its revenue for the next year to be between $173 million and $183 million.
HERON THERAPEUTICS ($HRTX) Releases Q4 2025 Earnings
HERON THERAPEUTICS ($HRTX) reported its Q4 2025 earnings, surpassing both earnings per share and revenue estimates. The company posted -$0.02 EPS against an estimated -$0.02, and revenue of $40,590,000, exceeding the $40,323,996 estimate. The article also details hedge fund activity, with a significant number of institutional investors adding and decreasing positions in HRTX stock, and notes a "Buy" rating from HC Wainwright & Co.
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results
Heron Therapeutics reported its financial results for Q4 and full-year 2025, showing a 7.4% increase in net revenue to $154.9 million, primarily driven by its Acute Care franchise products, ZYNRELEF® and APONVIE®. Despite a net loss, the company saw improved adjusted EBITDA and provided optimistic revenue and EBITDA guidance for 2026. Strategic advancements like a permanent J-Code for ZYNRELEF® and FDA approval anticipation for a new presentation underline its strengthened market position.
HERON THERAPEUTICS, INC. /DE/ SEC 10-K Report
HERON THERAPEUTICS, INC. has released its annual 10-K report, detailing a 7.4% increase in net product sales to $154.9 million, driven by acute care products, alongside a net loss of $20.2 million. The report highlights strategic shifts, including winding down SUSTOL commercialization while expanding ZYNRELEF and APONVIE, and addresses challenges such as market acceptance, supply chain risks, intense competition, and the critical need for additional capital. The company's future outlook focuses on capital management, strategic partnerships, and product development amidst global economic uncertainties.
Heron Therapeutics (NASDAQ:HRTX) Issues Earnings Results, Beats Estimates By $0.01 EPS
Heron Therapeutics (NASDAQ:HRTX) announced earnings that beat analysts' estimates by $0.01 EPS, reporting a quarterly loss of ($0.02) per share against predictions of ($0.03). The company also exceeded revenue expectations, bringing in $40.59 million compared to estimated $39.53 million. Key takeaways include strong acute care product growth, successful refinancing in 2025, and projections for continued net sales and positive adjusted EBITDA for 2026, despite planned increases in commercial investments.
Heron Therapeutics Inc expected to post a loss of 2 cents a share - Earnings Preview
Heron Therapeutics Inc (HRTX) is projected to report a loss of 2 cents per share, according to an earnings preview. This forecast is based on information from Refinitiv.
Heron Therapeutics (HRTX) Expected to Announce Earnings on Thursday
Heron Therapeutics (NASDAQ:HRTX) is expected to report its Q4 2025 earnings before market open on Thursday, February 26th, with analysts forecasting an EPS of ($0.03) and revenue of $39.533 million. The stock currently trades around $1.21, with a market capitalization of $221.9 million, and analysts have a consensus "Hold" rating with a target price of $4.50. Institutional investors and hedge funds hold a significant 80.01% stake, with several firms increasing their positions in recent quarters.
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
Heron Therapeutics will host a conference call and live webcast on February 26, 2026, at 8:30 a.m. ET to announce its fourth quarter and full year 2025 financial results and discuss recent business developments. The commercial-stage biotechnology company focuses on developing and commercializing therapeutic innovations for acute care and oncology patients. This announcement includes forward-looking statements regarding future expectations and risks.
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
Heron Therapeutics, Inc. announced it will host a conference call and live webcast on Thursday, February 26, 2026, at 8:30 a.m. ET. The purpose of the call is to report its fourth quarter and full year 2025 financial results and discuss recent business highlights. Interested parties can register for the call or access the webcast through the company's investor relations website.
Heron Therapeutics sets Feb. 26 webcast on 2025 results, business updates
Heron Therapeutics (Nasdaq: HRTX) will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, via a conference call and live webcast at 8:30 a.m. ET. The company will discuss financial performance and recent business highlights, with a replay available on their investor website for 60 days. This announcement continues Heron's pattern of regular communication regarding its financial results and business updates.
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
Heron Therapeutics, Inc. announced that it will host a conference call and live webcast on Thursday, February 26, 2026, at 8:30 a.m. ET. The call will cover the company's fourth quarter and full year 2025 financial results and recent business highlights. Interested parties can register via a link for dial-in details or access the webcast through the Investor Relations section of Heron’s website.
Here's Why Heron Therapeutics (NASDAQ:HRTX) Has A Meaningful Debt Burden
Heron Therapeutics (NASDAQ:HRTX) carries a significant debt burden, with US$139.7m in debt against US$55.5m in cash, resulting in net debt of US$84.2m as of September 2025. The company's weak interest cover of 0.41 times and a high net debt to EBITDA ratio of 21.3 indicate a concerning level of risk despite turning a yearly EBIT loss into a gain. Investors are advised to be cautious given the substantial debt and negative free cash flow.
Here's Why Heron Therapeutics (NASDAQ:HRTX) Has A Meaningful Debt Burden
Heron Therapeutics (NASDAQ:HRTX) carries a significant debt burden, with net debt of US$84.2m as of September 2025. The company's weak interest cover and high net debt to EBITDA ratio raise concerns about its financial risk, despite a recent improvement in EBIT. Analysts suggest the company's reliance on debt makes it a risky investment, particularly given its negative free cash flow.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Consensus Recommendation of "Hold" from Brokerages
Heron Therapeutics, Inc. (NASDAQ:HRTX) has received a "Hold" consensus rating from five brokerages. Analysts have issued an average one-year price target of $4.50 for the stock. Institutional investors have significantly increased their holdings in Heron Therapeutics, with several firms boosting their positions during the fourth quarter.
Heron Therapeutics, Inc. (HRTX): Investor Outlook Reveals Potential 240.91% Upside
Heron Therapeutics, Inc. (HRTX), a biotechnology company, is gaining investor attention despite current financial challenges, driven by its innovative Biochronomer technology and drug delivery systems. Analysts have a positive outlook, with a consensus target price suggesting a potential upside of 240.91% from current levels. The company's strategy involves reinvesting heavily in R&D to develop therapies like SUSTOL, CINVANTI, ZYNRELEF, and APONVIE, indicating a long-term growth focus for investors with a tolerance for volatility.
New York State Common Retirement Fund Buys 816,671 Shares of Heron Therapeutics, Inc. $HRTX
The New York State Common Retirement Fund significantly increased its stake in Heron Therapeutics, Inc. (HRTX) by 46.4% in the third quarter, acquiring 816,671 additional shares to hold a total of 2,576,716 shares valued at $3.25 million. Other institutional investors also adjusted their positions in the biotechnology company. Heron Therapeutics currently trades near its 52-week low, and analysts have an average "Hold" rating with a target price of $4.50.
Heron Therapeutics, Inc. (HRTX) Stock Analysis: Exploring A 238% Upside Potential
Heron Therapeutics, Inc. (HRTX) is attracting investor interest with analysts projecting a 238.35% upside potential, setting an average target price of $4.50. The biotechnology company, specializing in therapeutic solutions using its Biochronomer technology, shows positive revenue growth despite current financial challenges like negative EPS and free cash flow. While the stock's technical indicators are neutral, strong analyst sentiment with all "buy" ratings suggests optimism for its diverse product pipeline and market expansion.
Heron Therapeutics (NASDAQ:HRTX) Stock Passes Above Two Hundred Day Moving Average - Time to Sell?
Heron Therapeutics (NASDAQ:HRTX) stock recently passed above its 200-day moving average, a technical breakout, despite mixed analyst ratings with an average price target of $4.50. The company reported a quarterly EPS loss that missed expectations and slightly lower revenue. Institutional and hedge fund ownership of the stock is significant, holding approximately 80% of shares.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Consensus Recommendation of "Hold" from Analysts
Five analysts have issued an average "Hold" recommendation for Heron Therapeutics (NASDAQ:HRTX), with an average 1-year price target of $4.50. Despite significant institutional investment, including Clearline Capital increasing its stake by 1,033%, the company's near-term fundamentals appear weak, marked by a recent EPS miss and a negative P/E ratio. Shares currently trade around $1.49, falling within a 12-month range of $1.00 to $2.68.
Heron rises as preliminary revenue figures exceed estimates
This article provides an update on Heron's financial performance, noting that preliminary revenue figures have exceeded estimates. This positive news has led to an increase in the company's standing.
Great week for Heron Therapeutics, Inc. (NASDAQ:HRTX) institutional investors after losing 10% over the previous year
Heron Therapeutics, Inc. (NASDAQ:HRTX) saw a 10% stock gain last week, which is welcomed by its institutional investors, who hold a significant 57% stake in the company. Hedge funds own 27% with Rubric Capital Management LP as the largest shareholder at 16%. The general public holds 15%, while insiders own less than 1% of the US$255 million market cap company.
Heron Therapeutics’ Q4 Earnings Beat Forecasts, Boosted by Acute Care Success
Heron Therapeutics (HRTX) reported Q4 revenues exceeding forecasts, driven by strong performance from its acute care products, ZYNRELEF and APONVIE. Despite ongoing profitability concerns and a challenging market position, the company's stock rose by 12.6% due to these positive financial results and upward price momentum. The article highlights the importance of strategic focus on acute care to maintain growth and improve investor confidence.
Heron Therapeutics’ Revenue Soars Beyond Expectations in Q4 2025
Heron Therapeutics (HRTX) announced Q4 2025 revenue of $40.5 million, exceeding analyst expectations, primarily driven by strong contributions from its Acute Care franchise, particularly ZYNRELEF and APONVIE. The company's full-year 2025 net revenue reached $154.9 million, showcasing significant growth. Despite lingering profitability challenges like negative EBIT and pre-tax profit margins, the strong revenue performance and a nascent bullish technical trend for HRTX shares suggest potential for investor confidence.
Heron Therapeutics Revenue Exceeds Estimates with Strong Acute Care Performance
Heron Therapeutics (HRTX) has reported strong fourth-quarter 2025 revenue of $40.5 million, surpassing estimates, driven by its Acute Care franchise products ZYNRELEF and APONVIE. Despite this revenue growth and a high gross margin, the company faces significant profitability and financial strength challenges, including negative EBIT and profit margins, substantial debt, and a cautious market outlook. The stock has shown recent upward momentum, with key technical levels to watch for future movements.
Heron Therapeutics Surpasses Revenue Expectations with Significant Growth
Heron Therapeutics (HRTX) has seen its stock rise by 12.6% due to positive FDA feedback and strong quarterly revenues, particularly from its acute care products ZYNRELEF and APONVIE. While revenue growth is promising, the company still faces challenges with profitability and high leverage, indicating a need to focus on operational efficiencies and cost management to achieve sustained success. Analysts maintain a cautiously optimistic outlook, setting a price target of 1.50 for the stock.
Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M
Heron Therapeutics reported preliminary Q4 2025 revenue of approximately $40.5M, exceeding the consensus estimate of $39.83M, driven by strong growth in its Acute Care franchise with ZYNRELEF and APONVIE. The company's CEO, Craig Collard, expressed satisfaction with the revenue growth and overall business progress throughout the past year, with ZYNRELEF showing the largest quarter-over-quarter increase. Full-year 2025 net revenue reached approximately $154.9M.
Heron Therapeutics Expands Strategic Vision Amid Market Fluctuations
Heron Therapeutics (NASDAQ: HRTX) saw its stock rise by 12.6% due to optimistic FDA-related news. The company is adopting a dynamic strategic vision, navigating financial challenges with calculated risk-taking and innovation, as indicated by its latest quarterly report and speculation around potential new collaborations. Despite operational costs and a high debt-to-equity ratio, Heron Therapeutics aims for financial agility and strategic expansion.
Heron Therapeutics' (HRTX) "Buy" Rating Reiterated at HC Wainwright
HC Wainwright has reiterated a "Buy" rating for Heron Therapeutics (HRTX) with a price target of $6.00, suggesting a significant upside of over 300%. This re-affirmation comes despite mixed analyst coverage, which currently averages a "Hold" rating, and the company recently missed quarterly EPS and revenue estimates. Institutional investors hold approximately 80% of Heron Therapeutics' stock.
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth
Heron Therapeutics announced preliminary unaudited net revenues for Q4 and full-year 2025, reaching approximately $40.5 million and $154.9 million, respectively. ZYNRELEF was the largest contributor to Q4 growth, showing a 35% increase over Q3 2025. The company highlighted strong performance across its Acute Care franchise, including APONVIE, and overall business progress throughout the year.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Average Recommendation of "Hold" from Analysts
Heron Therapeutics, Inc. (NASDAQ:HRTX) has received an average "Hold" recommendation from analysts, with a consensus 1-year target price of $4.50. The company recently reported a quarterly EPS miss and revenue below expectations, with the stock currently trading around $1.28. Institutional investors hold approximately 80% of the shares, while the stock has seen a recent decline of 4.5%.
